Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation

Trial Profile

Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilacidin (Primary)
  • Indications Stomatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Innovation Pharmaceuticals
  • Most Recent Events

    • 09 May 2018 Results presented in an Innovation Pharmaceuticals Media Release.
    • 16 Apr 2018 Additional data presented in an Innovation Pharmaceuticals Media Release.
    • 09 Apr 2018 Results of subgroup analysis assessing the effect of Brilacidin on incidence of severe oral mucositis in head and neck cancer patients receiving chemoradiation (aggressive versus non-aggressive chemotherapy regimen), presented in an Innovation Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top